Moderna (mrna) Q2 2025 revenue

The Moderna logo can be seen on April 9, 2025 in Warsaw, Poland.

Jakub Porzycki | Nurphoto | Getty pictures

Modern On Friday, the upper end of his sales outlook from 2025 lowered due to a delay in the vaccine shipping to Great Britain, but exceeded the expectations of Wall Street for the second quarter because it lowers the costs.

Moderna's shares fell by more than 9%on Friday.

The biotech company now expects the turnover of the year to be between $ 1.5 billion and $ 2.2 billion, which is due to a decrease of $ 300 million at the top of this area. The results come in one day after Moderna announced plans to reduce 10% of its workforce, which has been reinforced to a number of cost cuts, while the company deals with the Covid vaccine with falling sales and tries to bring more products onto the market.

In an interview, the CFO of Moderna, Jamey Mock, said that Spring Covid Booster to Great Britain to Great Britain at the end of this year

“It is only about deliveries from our financial year to the financial year, which happens to be the first quarter of next year to meet the offer for the Spring Booster in Great Britain,” said Mock.

Also on Friday, the company stated that less than analysts were expected in the second quarter, and achieved sales that exceeded estimates.

Moderna reported in the second quarter compared to what Wall Street had expected, based on a survey of LSEG analysts:

• Loss per share: USD 2.13 compared to an expected loss of $ 2.97
• Revenue: Expected 142 million US dollars compared to 113 million US dollars

Moderna achieved sales of $ 142 million in the second quarter, which decreased to 41% in the same period last year, since sales with the turnover of covid vaccines used. The vast majority of sales in the second quarter came from the Covid shot, which corresponded to 114 million US dollars for the period.

This exceeded the 89 million US dollars, which analysts awaited Street Account for the period, according to estimates.

However, the company said that its vaccine against the Syncytial virus of respiratory tract “negligible” sales compared to the estimates of StreetCCOUNT had the analysts compared to USD 5.9 million.

The company recorded a net loss of $ 825 million or $ 2.13 per share for the second quarter. This is compared to a net loss of $ 1.3 billion or $ 3.33 per share, which was reported for the period of previous year's section.

Mock said Moderna's efforts to reduce costs helped the company to defeat estimates for the quarter. He said that the company's operating costs in the second quarter of $ 1.6 billion dropped by $ 27% to $ 1.1 billion in the same period last year.

“If it can really read from a first half [of 2025] From a financial point of view, it is on the cost side, ”said Mock.

Do not miss these findings from CNBC Pro